title: [Therapy of myopic choroidal neovascularization].
abstract: Recently published studies have shown that myopic choroidal neovascularization (mCNV) is efficiently treated by anti-vascular endothelial growth factor (VEGF) drugs. Within a prospective executive study, photodynamic therapy failed to prove a significant difference over the duration of 2 years. Although a systematic evaluation of different retreatment algorithms still has to be done the administration of single injections depending on specialist assessment of morphological changes, predominantly spectral domain optical coherence tomography (SD-OCT) and fundus, has achieved a marked visual improvement. The experience of treating age-related macular degeneration should not be simply transferred to mCNV and an individual approach, not only for female patients of childbearing age, is necessary.
authors: Department für Augenheilkunde, Universität Tübingen, Schleichstrasse 12-16, Tübingen, Germany. bogomil.voykov@gmail.com
authors: B
authors: B
authors: Voykov
authors: F
authors: F
authors: Ziemssen
authors: K U
authors: KU
authors: Bartz-Schmidt
mesh_terms: D020256:Choroidal Neovascularization / Q000150:complications / Q000473:pathology* / Q000628:therapy*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D009216:Myopia / Q000150:complications / Q000473:pathology* / Q000628:therapy*